One Bet, Now Final
The CY 2027 final Medicare payment rules confirm the direction CMS signaled in July. This analysis covers what changed from the proposed rules, where payment now splits by site of care, and what providers, manufacturers, and commercial teams should do before the rules take effect January 1, 2027.
Key Takeaways
- The skin substitute rate held, but site of care now splits the answer. Sheet products stay at $127.14/cm2 for CY 2027. Non-sheet products are nationally priced in the office but remain packaged in the hospital outpatient setting, and CMS's own OPPS rule text and payment file disagree on how their application is paid.
- The wound care visit pays less. The conversion factor finalized lower than proposed, and when a modifier-25 office E/M visit is billed with a 0-day procedure such as debridement or skin substitute application, every service but the highest-valued one is paid at 80%.
- CMS is pricing from market evidence, including what companies publish. CMS cut the ultrasonic wound therapy kit input from $320.18 to $125.00 using the manufacturer's own investor presentation. They also gave fluorescence wound imaging its first national rate while MACs propose noncoverage. The author contends 2027 is the year to build the CY 2028 evidence file and audit public disclosures.
In July, I argued that the Centers for Medicare & Medicaid Services’ (CMS's) two proposed rules were one bet, not five individual stories: care should move to the cheapest appropriate setting.1 The final rules are out, with 3,738 pages across the Physician Fee Schedule (PFS) and the Hospital Outpatient Prospective Payment System (OPPS), both effective January 1, 2027.2,3
The bet held. CMS softened one lever, kept the rest, and added a few that the proposals didn't show. 2026 reset the product price. 2027 holds that price and squeezes the visit around it.
Here's what moved, what it means for the market, and what providers, manufacturers, and commercial teams should do before January.
The Scorecard
Most of what the proposals signaled is now final policy. What changed was degree.
The flat skin substitute rate held.2,3 The same-day visit cut survived, smaller than proposed but now permanent policy.2,3 CMS floated a version of it in 2019 and backed off; this time it finalized one. The conversion factor came in lower than proposed. The ambulatory surgery center (ASC) Covered Procedures List grew by the 618 procedures CMS proposed, plus one more commenters requested.4 Fluorescence wound imaging got its national price.2,3
Two things moved more than expected. CMS delayed the contracted-staff restriction on remote monitoring by two years. And non-sheet skin substitutes got national pricing in the office but not in the hospital, which is a bigger story than the July proposal suggested.
The bet itself didn't change. CMS is still rewarding evidence, penalizing undifferentiated billing, and tightening where care pays.
The Rate That Still Didn't Move
Sheet-form skin substitutes stay at $127.14/cm2 across all three United States Food and Drug Administration (FDA)-category ambulatory payment classifications (APCs) (6000, 6001 and 6002) for CY2027.4,5 CMS says it doesn't have enough CY2026 claims data yet and will revisit rates in CY2028 rulemaking. It rejected the alternatives commenters proposed: per-cm2 rates of $478 to $715, invoice-based pricing and an inflation index.
A second year at the same rate locks in the restructuring 2026 started. Any business plan that assumed a regulatory rescue in 2027 needs a new assumption. CY2028 is still the year the market finds out how CMS differentiates. The proposed rule that will show it is about eight months away, and the evidence file July told manufacturers to build needs to be ready before then.
In July I wrote that the flat rate holds across all three sites of care.1 For sheet products, it still does. For non-sheet products, the final rules split it.2,3
The bigger change is for non-sheet products: gels, powders, and injectables. July covered CMS's proposal to fold them into national pricing. The final rules did that, but only in one setting.
In the office, under the PFS, non-sheet products are now paid at the same $127.14/cm2 as sheets, measured by wound surface area treated.6 CMS rejected arguments for volume- or depth-based units. The application codes (G0681–G0684) moved from contractor pricing to national values.7 Any non-sheet product that benefited from favorable local pricing loses that variability on January 1.
In the hospital, under the OPPS, non-sheet products stay packaged, with no separate product payment.4 CMS says these products aren't manufactured, applied or measured in a standardized way, and that it will continue to consider separate payment.
There is also a conflict in the published OPPS materials. The rule text says CMS is moving two of the application codes, G0681 and G0683, from packaged to separately paid. The OPPS Addendum B posted November 4 still lists both as packaged, with no payment rate.4,5 Claims process off the addendum. Until CMS reconciles the two, hospitals shouldn't count on separate application payment.
One smaller change belongs here too. CMS narrowed the Part B inflation rebate exclusion, so skin substitutes licensed as biologics under section 351 of the Public Health Service Act will be subject to rebates.6 It affects no current product, but it matters for any pipeline product on a BLA path.
For the market, the result is that the same non-sheet product now has two payment answers depending on where it's applied. That gives non-sheet products a payment advantage in the office and in mobile practices billing under the PFS. In hospital-based wound centers, sheet products are the better-paid choice.
The Visit Gets Cheaper
Start with the conversion factor. It finalized lower than proposed: $32.9548 for qualifying alternative payment model (APM) participants, down 1.83%, and $32.6286 for everyone else, down 2.31%.2 Every office visit and procedure is paid a little less before any code-specific change applies.
The same-day cut matters most for wound care, and it survived in narrower form. CMS proposed paying the most expensive service at 100% and everything else at 50% when a modifier-25 E/M visit lands on the same day as a global procedure. The final policy is narrower: 80% instead of 50%, and only for procedures with a 0-day global period.6 The 10- and 90-day globals are out.
Narrower doesn't help wound care much. Debridement and skin substitute application codes are 0-day globals. Assess the wound, debride or apply, bill the visit: that's the pattern this policy now discounts, by 20% on everything except the highest-valued service that day. CMS names podiatry, dermatology and otolaryngology as the specialties most affected, even at the reduced rate.6
July flagged a possible knock-on effect: if the E/M outvalues the application code on a given day, the application takes the discount.1 The Final Rule confirms the mechanism. Which service gets cut depends on how the codes billed that day compare in value.
Remote monitoring got a delay. CMS finalized the established-patient rule for RTM and the initiating-visit requirement for both RPM and RTM. The rule that only staff employed by the billing practice can deliver treatment-management time is delayed to January 1, 2029.2 Vendor-delivered models get two more years to adjust.
Podiatry practices reporting through the merit-based incentive payment system (MIPS) should note that CMS removed two measures from the Podiatry MIPS value pathway (MVP): offloading with remote monitoring and chronic wound outcomes.6
July said physician margin pressure turns into commercial pressure.1 That's now confirmed. When the visit pays less, providers weigh procedure time, supply cost and total episode cost harder, and every product conversation inherits that math.
Three Signals July Didn't Cover
Ultrasonic wound therapy gets repriced from the manufacturer's own numbers. CPT 97610 was nominated as potentially misvalued, and the nomination relied on the manufacturer's own investor presentation, which listed consumable cost at about $100 per procedure at list price. CMS footnoted that presentation when it agreed the code needed revaluation.6 The supply input for the single-use kit drops from $320.18 to $125.00. CMS had proposed $100 and settled on $125, the price commenters cited most often.
The effect on payment is large. Total office relative value units (RVUs) fall from 11.91 to 9.64, and the national office rate for qualifying APM participants goes from $399.82 to $317.68, a drop of $82.14 per service.7–9 The full revaluation cuts the code's total RVUs by more than 19%, so the statutory phase-in applies: CY2027 takes the first step, and the rest arrives in a later year. CMS hasn't published that later figure.
The hospital side moved the other way. The code's OPPS status changed so it's always separately paid, at $235.04, including when it's billed the same day as debridement. Previously it was packaged in that situation.4,5
This goes beyond one code. CMS reads investor materials, and it will use a company's own disclosures to set its reimbursement. Any device-plus-consumable business that publishes unit economics should assume they're inputs.
Fluorescence wound imaging gets a price, not coverage. July reported the move from Category III codes to a permanent Category I code, with valuation based largely on manufacturer-supplied inputs. It's now CPT 97611. In CY2026, the predecessor codes were contractor-priced, with no national rate.8 For CY2027, CMS finalized the 0.80 work RVU over requests to leave pricing to contractors.6 The national rate is $109.74 in the office and $244.85 in the hospital.5,7 On the supply duplication question July raised, CMS removed only two items, a surgical blade and a silver nitrate applicator.
A national rate is not coverage. Medicare Administrative Contractors have proposed noncoverage for this technology, and nothing in either final rule changes that. If those policies finalize, providers will bill a nationally priced code that is denied as not reasonable and necessary. Coded is not covered.10
Breakthrough designation no longer buys a shortcut to pass-through. CMS closed the alternative pathway that let Breakthrough Devices qualify for OPPS transitional pass-through payment without demonstrating substantial clinical improvement. CMS finalized the change in the FY2027 IPPS final rule and restated it in the OPPS rule. It applies to applications received on or after October 1, 2026. A limited exception covers devices that had Breakthrough designation by September 30, 2026, and have marketing authorization for that indication; complete applications are due by March 1, 2028.4 Wound technologies that planned around that pathway now need the clinical case.
WISeR: Still Standing
Neither final rule touches WISeR. July said to plan as if the prior authorization model were permanent. Four months later, the challenges haven't stopped it.
The Senate's Congressional Review Act resolution to end the model failed 46–50 in July, and as of this month (November 2026) the program remains active.11 The House Appropriations Committee's rider to block WISeR funding sits in a FY2027 Labor-HHS bill that hasn't been enacted.12,13 The government is running on a continuing resolution through December 11, 2026.12,14 December is the next decision point.
Meanwhile, the model is operating. The gold-card exemption program was scheduled to launch July 6.15 Early Texas data reported by one law firm showed initial affirmation rates around 62%, against a 92% national average under traditional Medicare.16
For skin substitutes in the six WISeR states, the two policies stack. A same-day application now carries both the 20% reduction and prior authorization. In those states, documentation decides payment.
The Thread Connecting All of It
The playbook is the same one CMS has run since it reset skin substitute payment for 2026: reward evidence, penalize undifferentiated billing, and narrow where treatment pays.
What's new this cycle is how CMS gets its numbers. It priced an ultrasonic therapy kit using a company's investor deck. It valued fluorescence imaging with no specialty survey, pricing the equipment from manufacturer invoices. It held the skin substitute rate until it has a full year of CY2026 claims data to work from. CMS is valuing codes on market evidence, and that evidence includes what companies say about themselves.
The other shift: site of care now decides whether something is paid separately, and how much. A non-sheet product is paid in the office and packaged in the hospital. Ultrasonic wound therapy lost ground in the office and gained it in the hospital. Fluorescence imaging pays more than twice as much in the hospital as in the office. For the same product, the commercial case now depends on where it's used.
What to Do With This
Providers and wound centers. The same-day reduction and the conversion factor cut take effect January 1, whatever happens with WISeR. Before then, I recommend the following:
- Re-run per-visit revenue for your most common encounter types (E/M plus debridement, E/M plus application) at the new rates.
- Review how modifier 25 is documented. A smaller payment on the second service raises the stakes on showing the visit was separately identifiable.
- If you use fluorescence imaging, track the MAC coverage decisions and use Advance Beneficiary Notices where appropriate. A national rate won't protect a denied claim.
- Hospital outpatient departments should confirm with billing how non-sheet application codes will be handled in January, given the OPPS conflict.
- In the six WISeR states, treat documentation as part of the payment process.
Manufacturers. 2027 is a build year with a deadline. CY2028 rulemaking is when CMS says it will revisit the rate.
- Build the CY2028 evidence file now: clinical outcomes, health economics, coding accuracy and utilization. Have it ready before the proposed rule lands next summer.
- Model each site of care separately. Office and hospital economics now diverge for non-sheet products, ultrasonic therapy and imaging.
- Audit your public disclosures. Investor decks, earnings calls and list prices are now potential valuation inputs.
- If your reimbursement plan assumed Breakthrough-to-pass-through, rebuild it around substantial clinical improvement.
Commercial and distribution teams. The pitch changes because the customer's math changes.
- Lead with encounter economics (procedure time, supply cost, total cost of the episode), not product rate. Every sheet product carries the same rate now.
- Segment accounts by site of care and reimbursement readiness. Office, mobile, and hospital accounts need different conversations, and in WISeR states, providers with clean documentation are easier to keep.
- Bring reimbursement expertise to the account. Customers need help with the January changes, and the reps who can explain them keep the accounts.
What to watch. CMS reconciling the OPPS conflict on non-sheet application codes, likely through a correction notice or the January quarterly update. MAC final decisions on wound imaging coverage. The December 11 funding deadline and the WISeR rider. The CY2028 proposed rule next summer, including the next phase of the ultrasonic therapy cut. And the December 31, 2027 telehealth sunset, which makes 2027 the last year of planning certainty before that cliff returns.
In July I said to redo the math. The numbers are now final, and they take effect January 1.
Scott Nelson is the founder of Below The Knee, an independent market intelligence platform covering wound care, limb salvage, and vascular intervention. He also holds a commercial role at Swift Medical, a wound care technology company.
References
1. Nelson S. Five Moves - One Bet: What CMS Is Really Telling the Wound Care Industry. HMP Global Learning Network. Published July 24, 2026. Accessed November 10, 2026. https://www.hmpgloballearningnetwork.com/site/wounds/news/five-moves-one-bet-what-cms-really-telling-wound-care-industry
2. Centers for Medicare & Medicaid Services. Calendar Year (CY) 2027 Medicare Physician Fee Schedule Final Rule (CMS-1848-F) fact sheet. Published November 4, 2026. Accessed November 5, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-medicare-physician-fee-schedule-final-rule
3. Centers for Medicare & Medicaid Services. Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule (CMS-1850-F) fact sheet. Published November 4, 2026. Accessed November 5, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-2027-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center-0
4. Centers for Medicare & Medicaid Services. CY 2027 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; final rule (CMS-1850-F). https://www.cms.gov/newsroom/fact-sheets/calendar-year-2027-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center-0
5. Centers for Medicare & Medicaid Services. CY 2027 OPPS Final Rule Addendum B (CMS-1850-F). Dated November 4, 2026. https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices/cms-1850-fc
6. Centers for Medicare & Medicaid Services. CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; final rule (CMS-1848-F). Display copy. https://www.federalregister.gov/documents/2026/11/09/2026-22743/medicare-and-medicaid-programs-cy-2027-payment-policies-under-the-physician-fee-schedule-and-other
7. Centers for Medicare & Medicaid Services. CY 2027 PFS Final Rule Addendum B: Relative Value Units and Related Information (CMS-1848-F). https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1848-f
8. Centers for Medicare & Medicaid Services. CY 2026 PFS Final Rule Addendum B: Relative Value Units and Related Information (CMS-1832-F). Dated November 3, 2025. https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1832-f
9. Centers for Medicare & Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) fact sheet. Accessed November 5, 2026. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
10. Nelson S. Coded But Not Covered. Below The Knee. Published October 3, 2026. https://www.belowtheknee.co/insights/coded-but-not-covered
11. Medicare's AI prior authorization pilot had 4 of 6 vendors flagged in first weeks, records show. Tech Times. Published November 3, 2026. Accessed November 5, 2026. https://www.techtimes.com/articles/329935/20261103/medicares-ai-prior-authorization-pilot-had-4-6-vendors-flagged-first-weeks-records-show.htm
12. Congressional Research Service. Status of FY2027 Labor, Health and Human Services, and Education Appropriations: In Brief (R49344). Accessed November 5, 2026. https://www.congress.gov/crs-product/R49344
13. Morse S. House Appropriations Committee votes to end funding for WISeR pilot. Healthcare Finance News. Published June 11, 2026. Accessed November 5, 2026. https://www.healthcarefinancenews.com/news/house-appropriations-committee-votes-end-funding-wiser-pilot
14. Committee for a Responsible Federal Budget. Appropriations Watch: FY 2027. Updated September 3, 2026. Accessed November 5, 2026. https://www.crfb.org/blogs/appropriations-watch-fy-2027
15. Washington State Medical Association. Latest updates on WISeR prior authorization pilot program. Published April 17, 2026. Accessed November 5, 2026. https://wsma.org/latest-news/2026/latest-updates-on-wiser-prior-authorization-pilot-program/
16. CMS set to launch WISeR gold-carding exemption program. National Law Review. Accessed November 5, 2026. https://natlawreview.com/article/willy-wonka-and-wiser-did-you-get-golden-ticket


